Benralizumab for HES get orphan drug tagApril 9, 2019
The US FDA has granted Orphan Drug designation benralizumab (Fasenra) for the treatment of hypereosinophilic syndrome (HES).
HES is a group of rare, potentially fatal disorders characterised by high numbers of eosinophils in blood and tissues, which can cause progressive damage to any organ in the body.
Benralizumab is a monoclonal antibody that binds directly to IL-5 receptor on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis.
Benralizumab was developed by AstraZeneca with MedImmune.